SCHEMBL5148804

SCHEMBL5148804

Cc1ccc(-n2nc(C(F)(F)F)cc2-c2ccc(C#N)cc2)cc1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 9/20 0.66
CYP2C9 P11712 3/20 0.66
PDPK1 O15530 4/20 0.65
PTGS1 P23219 6/20 0.65
HDAC3 O15379 2/20 0.65
HDAC4 P56524 2/20 0.65
HDAC1 Q13547 2/20 0.65
HDAC7 Q8WUI4 2/20 0.65
HDAC2 Q92769 2/20 0.65
HDAC10 Q969S8 2/20 0.65
HDAC11 Q96DB2 2/20 0.65
HDAC8 Q9BY41 2/20 0.65
HDAC6 Q9UBN7 2/20 0.65
HDAC9 Q9UKV0 2/20 0.65
HDAC5 Q9UQL6 2/20 0.65
PTGES O14684 1/20 0.65
CA12 O43570 1/20 0.65
PDE5A O76074 1/20 0.65
ABCB11 O95342 1/20 0.65
MT-CO2 P00403 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5148756 1.00 PTGS2 (0.66) PTGS2CYP2C9PDPK1PTGS1HDAC3
SCHEMBL8266070 0.89 PTGS2 (0.80) PTGS2CYP2C9PDPK1PTGS1HDAC3
SCHEMBL5147944 0.86 PTGS2 (0.81) PTGS2CYP2C9PDPK1PTGS1CYP3A4
SCHEMBL7461307 0.86 PTGS2 (0.67) PTGS2CYP2C9PDPK1PTGS1HDAC3
SCHEMBL5148706 0.86 PTGS2 (0.81) PTGS2CYP2C9PDPK1PTGS1CYP3A4
SCHEMBL7466476 0.85 PTGS2 (0.74) PTGS2CYP2C9PDPK1PTGS1HDAC3
SCHEMBL7468098 0.84 PDPK1 (0.59) PTGS2CYP2C9PDPK1PTGS1HDAC3
SCHEMBL27638004 0.84 PDPK1 (0.61) PTGS2CYP2C9PDPK1PTGS1
SCHEMBL27638007 0.84 PDPK1 (0.61) PTGS2CYP2C9PDPK1PTGS1
SCHEMBL4587051 0.84 PTGS2 (0.73) PTGS2CYP2C9PDPK1PTGS1HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1567503-B1 PYRAZOLE DERIVATIVES USEFUL AS COX-I INHIBITORS ASTELLAS PHARMA INC (JP) 2011-12-21 EP disclosed
US-20070112037-A1 Pyrazole Derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2007-05-17 US disclosed
US-7183306-B2 Pyrazole derivatives ASTELLAS PHARMA INC. (JP) 2007-02-27 US disclosed
EP-1567503-A1 PYRAZOLE DERIVATIVES USEFUL AS COX-I INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-08-31 EP disclosed
US-20040116475-A1 Pyrazole derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-06-17 US disclosed
WO-2004050632-A1 PYRAZOLE DERIVATIVES USEFUL AS COX-I INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112037-A1 Pyrazole Derivatives CYP11B2, CYP11B1, CYP3A43 PTGS2 1780/4885CYP2C9 55/4885PDPK1 2205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.